Last reviewed · How we verify
Daclatasvir Zeta — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Daclatasvir Zeta (Daclatasvir Zeta) — Genuine Research Center, Egypt.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Daclatasvir Zeta TARGET | Daclatasvir Zeta | Genuine Research Center, Egypt | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Daclatasvir Zeta CI watch — RSS
- Daclatasvir Zeta CI watch — Atom
- Daclatasvir Zeta CI watch — JSON
- Daclatasvir Zeta alone — RSS
Cite this brief
Drug Landscape (2026). Daclatasvir Zeta — Competitive Intelligence Brief. https://druglandscape.com/ci/daclatasvir-zeta. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab